Asset 1

AllCells’ scientists will remain part of Discovery, and all ongoing studies will continue to be serviced by those same dedicated experts. The flow of projects and timelines will be unaffected by the acquisition.

Quick Links

Technologies

Development and Clinical
Trial Solutions